Aprea Therapeutics Gains 2025 Patents in Australia and Japan, Securing 2042–2045 Exclusivity
Aprea Therapeutics secured patents in 2025 for its WEE1 and ATR inhibitors in Australia and Japan, extending exclusivity to 2042 and potentially 2045. Its lead WEE1 candidate APR-1051 is in Phase 1 trials with multiple clinical data readouts expected in 2026.
1. Patent Portfolio Expansion
Aprea secured one WEE1 patent in Australia and one ATR patent in Japan in 2025, supplemented by two pending U.S. and 13 international WEE1 applications and 21 granted plus 15 pending ATR filings. Issued WEE1 patents extend protection to 2042, while pending ATR patents could push exclusivity into 2045.
2. WEE1 Inhibitor Program Progress
Lead candidate APR-1051 is being evaluated in the ACESOT-1051 Phase 1 trial for advanced and metastatic solid tumors with specific gene alterations. Early proof-of-concept has been demonstrated and multiple clinical data readouts are anticipated throughout 2026.
3. ATR Inhibitor Protection
ATRN-119, Aprea’s ATR inhibitor, is in the ABOYA-119 monotherapy trial in advanced solid tumors. The ATR portfolio includes four issued U.S. patents, one pending U.S. application, one international application and existing patents active until 2035–37.
4. Strategic Implications
The expanded global IP estate and ongoing clinical progress de-risk development and enhance long-term value creation, positioning Aprea for future partnerships or strategic transactions. Extended exclusivity through the 2040s supports potential commercialization across multiple oncology indications.